S. Olindo

Dr. S. Olindo


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2021 in Journal of Stroke
Verified
Journal Article
Open access
PDF file
SOS. Olindo
S. Olindo
NCNicolas Chausson
Nicolas Chausson
ASAissatou Signate
Aissatou Signate
SMSylvie Mecharles
Sylvie Mecharles
JHJean-Luc Hennequin
Jean-Luc Hennequin
JJJulien Joux
Julien Joux
Background and Purpose Carotid web (CaW) is an intimal variant of fibromuscular dysplasia responsible for ipsilateral cerebral ischemic events (CIE). Symptomatic CaW likely has a high risk of recurrent CIE, but no salient prospective data are available. We aimed to assess recurrence rate and its predictors after a first-ever CIE.Methods Consecutive Afro-Caribbean patients who had cryptogenic first-ever CIEs (ischemic stroke [IS] or transient ischemic attack [TIA]) associated with ipsilateral CaW were included in this multicenter observational cohort study. The follow-up (January 2008 to March 2019) focused on CIE recurrences. Kaplan-Meier method assessed rates of recurrences and Cox proportional hazards regression analyzed risk factors.Results Ninety-two patients (79 first-ever ISs and 13 TIAs; mean age±standard deviation, 49.8±9.9 years; 52 [56.5%] women) were included. During a mean follow-up of 50.5±29.6 months, 19 (20.7%) patients experienced recurrent ipsilateral CIEs (16 ISs and three TIAs). Of 23 patients receiving surgery/stenting treatment, no recurrence occurred after the intervention (median follow-up, 39.8 months [interquartile range, 27.6 to 72.4]). Under medical treatment alone, the annual recurrent CIE rate was 6.9%, and the cumulative rate was 4.4% at 30-day, 10.8% at 1-year, 19.8% at 2-year, 23.2% at 3-year, and 27.3% at 5-year. Presence of silent cerebral infarctions was the only independent risk factor of CIE recurrences (hazard ratio, 6.99; 95% confidence interval, 2.4 to 20.4; P=0.004).Conclusions Under medical treatment alone, symptomatic CaW was associated with a high rate of recurrence that reached 27.3% at 5-year. Surgery/stenting seems to be efficient, and randomized control trials are required to confirm the benefit of these interventions.

1 October 2023 in Stroke
Verified
Journal Article
Closed access
TCThomas Checkouri
Thomas Checkouri
GGGaspard Gerschenfeld
Gaspard Gerschenfeld
PSPierre Seners
Pierre Seners
MYMarion Yger
Marion Yger
WHWagih Ben Hassen
Wagih Ben Hassen
LSLaurent Spelle
Laurent Spelle
BACKGROUND: Intravenous thrombolysis (IVT) with alteplase or tenecteplase before mechanical thrombectomy is the recommended treatment for large-vessel occlusion acute ischemic stroke. There are divergent data on whether these agents differ in terms of early recanalization (ER) rates before mechanical thrombectomy, and little data on their potential differences stratified by ER predictors such as IVT to ER evaluation (IVT-to-ER eval ) time, occlusion site and thrombus length. METHODS: We retrospectively compared the likelihood of ER after IVT with tenecteplase or alteplase in anterior circulation large-vessel occlusion acute ischemic stroke patients from the PREDICT-RECANAL (alteplase) and Tenecteplase Treatment in Ischemic Stroke (tenecteplase) French multicenter registries. ER was defined as a modified Thrombolysis in Cerebral Infarction score 2b-3 on the first angiographic run, or noninvasive vascular imaging in patients with early neurological improvement. Analyses were based on propensity score overlap weighting (leading to exact balance in patient history, stroke characteristics, and initial management between groups) and confirmed with adjusted logistic regression (sensitivity analysis). A stratified analysis based on pre-established ER predictors (IVT-to-ER eval time, occlusion site, and thrombus length) was conducted. RESULTS: Overall, 1865 patients were included. ER occurred in 156/787 (19.8%) and 199/1078 (18.5%) patients treated with tenecteplase or alteplase, respectively (odds ratio, 1.09 [95% CI, 0.83–1.44]; P =0.52). A differential effect of tenecteplase versus alteplase on the probability of ER according to thrombus length was observed ( P interaction =0.003), with tenecteplase being associated with higher odds of ER in thrombi >10 mm (odds ratio, 2.43 [95% CI, 1.02–5.81]; P =0.04). There was no differential effect of tenecteplase versus alteplase on the likelihood of ER according to the IVT-to-ER eval time ( P interaction =0.40) or occlusion site ( P interaction =0.80). CONCLUSIONS: Both thrombolytics achieved ER in one-fifth of patients with large-vessel occlusion acute ischemic stroke without significant interaction with IVT-to-ER eval time and occlusion site. Compared with alteplase, tenecteplase was associated with a 2-fold higher likelihood of ER in larger thrombi.

1 May 2019 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
SSSharmila Sagnier
Sharmila Sagnier
FMFanny Munsch
Fanny Munsch
ABAntoine Bigourdan
Antoine Bigourdan
SDSabrina Debruxelles
Sabrina Debruxelles
MPMathilde Poli
Mathilde Poli
ISIgor Sibon
Igor Sibon

1 August 2021 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
CTC. Turpinat
C. Turpinat
FCF.L. Collemiche
F.L. Collemiche
CAC. Arquizan
C. Arquizan
NMN. Molinari
N. Molinari
FCF. Cagnazzo
F. Cagnazzo
NGN. Gaillard
N. Gaillard

1 November 2018 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
CTCyrielle Tomich
Cyrielle Tomich
SDSabrina Debruxelles
Sabrina Debruxelles
YDYahsou Delmas
Yahsou Delmas
SSSharmila Sagnier
Sharmila Sagnier
MPMathilde Poli
Mathilde Poli
ISIgor Sibon
Igor Sibon

25 August 2016 in BMC Geriatrics
Verified
Journal Article
Open access
PDF file
ISIgor Sibon
Igor Sibon
PGP. Galli
P. Galli
MPM. Poli
M. Poli
SDS. Debruxelles
S. Debruxelles
PRP. Renou
P. Renou
ISIgor Sibon
Igor Sibon
Age increases the risk of mortality and poor prognosis following stroke. The benefit of intravenous thrombolysis in very old patients remains uncertain. The purpose of the study was to evaluate the efficacy and safety of thrombolysis in very old patients considering their perfusion-imaging profile. We conducted a retrospective study including patients older than 90 y.o. admitted for an acute ischemic stroke. A computed tomography perfusion-imaging (CTP) was performed in patients who received thrombolysis. Primary outcome was the functional status at 3 months, assessed by the modified Rankin scale (mRS). Secondary outcomes were the rate of hemorrhagic transformations, duration of hospitalization and the rate of death in the first 7 days. Patients receiving thrombolysis were compared with an age-matched group of non-thrombolysed patients. 78 patients were included (31 % male, aged 92 ± 1.7 y.o). 37 patients received thrombolysis and among them, 30 had CTP with a mismatch. The three months mRS was not significantly different in the two groups (mRS 0–2: 5 % and 7 % in the thrombolysed and non-thrombolysed group, respectively). Hemorrhagic transformations were more frequent in the thrombolysed group (54 % versus 12 %, p = 0.002) and symptomatic intracranial hemorrhage tended to be associated with mRS at three months and death in the first 7 days. Duration of hospitalization was longer in the thrombolysed group (10 days ± 12 versus 7 days ± 9, p = 0.046). Patients who received thrombolysis did not have a better functional prognosis than non-thrombolysed patients.